GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics BuyoutInvestors Business Daily • 01/20/26
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 MillionBusiness Wire • 01/20/26
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drugMarket Watch • 01/20/26
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ TechnologyPRNewsWire • 01/20/26
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)Business Wire • 01/12/26
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage StudiesZacks Investment Research • 01/08/26
GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and DevelopmentBusiness Wire • 01/08/26
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B StudiesBenzinga • 01/07/26
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSKPRNewsWire • 12/21/25
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients payWSJ • 12/19/25